Treatment of osteoporosis in women intolerant of oral bisphosphonates

Maturitas

Volumn 71, Issue 1, 2012, Pages 76-78

  Aspray, Terry J ^a,b   Francis, Roger M ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Intolerant; Oral bisphosphonates; Osteoporosis; Treatment; Women

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; CALCIUM; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; STRONTIUM; STRONTIUM RANELATE; ZOLEDRONIC ACID;

DRUG WITHDRAWAL; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; HYPOCALCEMIA; KIDNEY FUNCTION; LIFESTYLE; OSTEOPOROSIS; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; VITAMIN D DEFICIENCY;

EID: 84855470694     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.10.005     Document Type: Short Survey

References (25)

1. Osteoporosis prevention, diagnosis, and therapy 2000 National Institute for Health Bethesda, Maryland, USA NIH Consensus Statement Online; 17(1): 1-36.
2. R. Burge, D. Worley, A. Johansen, and U. Bose The cost of osteoporotic fractures in the United Kingdom Value in Health 4 2 2001 66 67
3. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group (WHO Technical Report Series, No. 843). Geneva: World Health Organization, 1994.
4. J. Steurer, C. Haller, H. Hauselmann, F. Brunner, and L.M. Bachmann Clinical value of prognostic instruments to identify patients with an increased risk for osteoporotic fractures: systematic review PloS One 6 5 2011 e19994
5. N.M. Cummins, E.K. Poku, M.R. Towler, O.M. O'Driscoll, and S.H. Ralston Clinical risk factors for osteoporosis in Ireland and the UK: a comparison of FRAX and QFractureScores Calcified Tissue International 89 2 2011 172 177
6. G.A. Wells, A. Cranney, and J. Peterson Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database of Systematic Reviews 1 2008 CD001155
7. G.A. Wells, A. Cranney, and J. Peterson Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database of Systematic Reviews 1 2008 CD003376
8. G. Wells, A. Cranney, and J. Peterson Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database of Systematic Reviews 1 2008 CD004523
9. J.F. Committee British national formulary 61st ed 2011 British Medical Association and Royal Pharmaceutical Society of Great Britain London and Chicago
10. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE technology appraisal guidance 160 (amended) 2011 National institute for Health and Clinincal Excellence (NICE) London
11. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE technology appraisal guidance 161 (amended) 2011 National institute for Health and Clinincal Excellence (NICE) London
12. M.M. Wilkes, R.J. Navickis, W.W. Chan, and E.M. Lewiecki Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials Osteoporosis International 21 4 2010 679 688
13. M. Kamatari, S. Koto, and N. Ozawa Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate Journal of Bone & Mineral Metabolism 25 5 2007 302 309 (Pubitemid 47283269)
14. A.D. Anastasilakis, D.G. Goulis, M. Kita, and A. Avramidis Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases Hormones (Athens) 6 3 2007 233 241
15. S. Silverman, H.N. Viswanathan, and Y.C. Yang Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial Osteoporosis International 2011
16. B. Abrahamsen, P. Eiken, and R. Eastell Proton pump inhibitor use and the antifracture efficacy of alendronate Archives of Internal Medicine 171 11 2011 998 1004
17. M. Stevenson, S. Davis, M. Lloyd-Jones, and C. Beverley The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women Health Technology Assessment 11 4 2007 1 134
18. J.A. Kanis, H. Johansson, A. Oden, and E.V. McCloskey A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX Bone 47 4 2010 729 735
19. M.C. Chapuy, R. Pamphile, and E. Paris Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study Osteoporosis International 13 3 2002 257 264 (Pubitemid 34408194)
20. D.M. Black, P.D. Delmas, and R. Eastell Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis New England Journal of Medicine 356 18 2007 1809 1822 (Pubitemid 46698462)
21. P. Sambrook, A. Cranney, and J.D. Adachi Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA Current Medical Research and Opinion 26 3 2010 599 604
22. G. Scotland, N. Waugh, P. Royle, P. McNamee, R. Henderson, and R. Hollick Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal Pharmaco Economics 2011
23. R.M. Neer, C.D. Arnaud, and J.R. Zanchetta Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis The New England Journal of Medicine 344 19 2001 1434 1441 (Pubitemid 32402100)
24. E. Shane, D. Burr, and P.R. Ebeling Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research Journal of Bone and Mineral Research 25 11 2010 2267 2294
25. V. Patel, N.M. McLeod, S.N. Rogers, and P.A. Brennan Bisphosphonate osteonecrosis of the jaw - a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention The British Journal of Oral & Maxillofacial Surgery 49 4 2011 251 257